By Fineline Cube 
Taiwan-based OBI Pharma announced a collaboration with San Francisco-based TegMine Therapeutics, Inc. to develop antibody-drug conjugates (ADCs). TegMine specializes in innovative antibody therapies targeting cancer-associated glycoproteins, while OBI Pharma focuses on novel anti-cancer drugs and next-generation ADC development.
Collaboration Details
Under the agreement, the two companies will combine OBI’s proprietary GlycOBI glycosylation platform, EndoSymeOBI bifunctional enzyme, and HYPrOBI linker technology to develop ADC candidates with clinical potential. This strategic partnership aims to enhance ADC development by leveraging OBI’s advanced technology platforms.
Future Licensing Agreement
If successful in developing ADC candidates, the collaboration may lead to a formal licensing agreement between the two companies.-Fineline Info & Tech